Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBT Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBT Margin for 3 consecutive years, with 164.92% as the latest value for Q1 2025.

  • Quarterly EBT Margin changed N/A to 164.92% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 1304.75% through Dec 2025, changed N/A year-over-year, with the annual reading at 1304.75% for FY2025, N/A changed from the prior year.
  • EBT Margin for Q1 2025 was 164.92% at Centessa Pharmaceuticals, down from 1388.83% in the prior quarter.
  • The five-year high for EBT Margin was 3913.07% in Q2 2022, with the low at 164.92% in Q1 2025.
  • Average EBT Margin over 3 years is 2147.61%, with a median of 1997.43% recorded in 2023.
  • Peak annual rise in EBT Margin hit -60104bps in 2023, while the deepest fall reached -191564bps in 2023.
  • Over 3 years, EBT Margin stood at 1989.88% in 2022, then crashed by -30bps to 1388.83% in 2023, then tumbled by -112bps to 164.92% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 164.92%, 1388.83%, and 1632.19% for Q1 2025, Q4 2023, and Q3 2023 respectively.